GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » EV-to-EBITDA

Scandion Oncology A/S (OSTO:SCOL) EV-to-EBITDA : -0.64 (As of Jun. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scandion Oncology A/S's enterprise value is kr41.46 Mil. Scandion Oncology A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-64.73 Mil. Therefore, Scandion Oncology A/S's EV-to-EBITDA for today is -0.64.

The historical rank and industry rank for Scandion Oncology A/S's EV-to-EBITDA or its related term are showing as below:

OSTO:SCOL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -55.1   Med: -21.9   Max: 0.5
Current: -0.64

During the past 7 years, the highest EV-to-EBITDA of Scandion Oncology A/S was 0.50. The lowest was -55.10. And the median was -21.90.

OSTO:SCOL's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.42 vs OSTO:SCOL: -0.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), Scandion Oncology A/S's stock price is kr0.498. Scandion Oncology A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.435. Therefore, Scandion Oncology A/S's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Scandion Oncology A/S EV-to-EBITDA Historical Data

The historical data trend for Scandion Oncology A/S's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S EV-to-EBITDA Chart

Scandion Oncology A/S Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -8.49 -21.74 -3.29 -0.01 -1.88

Scandion Oncology A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.20 -0.07 -1.88 -1.19

Competitive Comparison of Scandion Oncology A/S's EV-to-EBITDA

For the Biotechnology subindustry, Scandion Oncology A/S's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scandion Oncology A/S's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology A/S's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Scandion Oncology A/S's EV-to-EBITDA falls into.



Scandion Oncology A/S EV-to-EBITDA Calculation

Scandion Oncology A/S's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=41.457/-64.731
=-0.64

Scandion Oncology A/S's current Enterprise Value is kr41.46 Mil.
Scandion Oncology A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-64.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandion Oncology A/S  (OSTO:SCOL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Scandion Oncology A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.498/-0.435
=At Loss

Scandion Oncology A/S's share price for today is kr0.498.
Scandion Oncology A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.435.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Scandion Oncology A/S EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Scandion Oncology A/S's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines